The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Smad3 as a mediator of the fibrotic response
Open accessAbstract
Summary: Transforming growth factor‐β (TGF‐β) plays a central role in fibrosis, contributing to the influx and activation of inflammatory cells, the epithelial to mesenchymal transdifferentiation (EMT) of cells and the influx of fibroblasts and their subsequent elaboration of extracellular matrix. TGF‐β signals through transmembrane receptor serine/threonine kinases to activate novel signalling intermediates called Smad proteins, which modulate the transcription of target genes. The use of mice with a targeted deletion of Smad3, one of the two homologous proteins which signals from TGF‐β/activin, shows that most of the pro‐fibrotic activities of TGF‐β are mediated by Smad3. Smad3 null inflammatory cells and fibroblasts do not respond to the chemotactic effects of TGF‐β and do not autoinduce TGF‐β. The loss of Smad3 also interferes with TGF‐β‐mediated induction of EMT and genes for collagens, plasminogen activator inhibitor‐1 and the tissue inhibitor of metalloprotease‐1. Smad3 null mice are resistant to radiation‐induced cutaneous fibrosis, bleomycin‐induced pulmonary fibrosis, carbon tetrachloride‐induced hepatic fibrosis as well as glomerular fibrosis induced by induction of type 1 diabetes with streptozotocin. In fibrotic conditions that are induced by EMT, such as proliferative vitreoretinopathy, ocular capsule injury and glomerulosclerosis resulting from unilateral ureteral obstruction, Smad3 null mice also show an abrogated fibrotic response. Animal models of scleroderma, cystic fibrosis and cirrhosis implicate involvement of Smad3 in the observed fibrosis. Additionally, inhibition of Smad3 by overexpression of the inhibitory Smad7 protein or by treatment with the small molecule, halofuginone, dramatically reduces responses in animal models of kidney, lung, liver and radiation‐induced fibrosis. Small moleucule inhibitors of Smad3 may have tremendous clinical potential in the treatment of pathological fibrotic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Deficient Smad7 expression: A putative molecular defect in scleroderma
Dong, C., Zhu, S., Wang, T., Yoon, W., Li, Z., Alvarez, R. J., ten Dijke, P., White, B., Wigley, F. M., & Goldschmidt-Clermont, P. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062010399 · Cited by 244
RetractedMassagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
Molecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus
Shi, Y., & Massagué, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00432-x · Cited by 5,857
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Transforming Growth Factor β in Tissue Fibrosis
Epstein, F. H., Border, W. A., & Noble, N. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311907 · Cited by 3,069
Handbook of Experimental Pharmacology.
Meakin, J. W. (1971) · Archives of Internal Medicine · doi:10.1001/archinte.1971.00310230151026 · Cited by 1,959
Transforming growth factor beta
(2011) · SpringerReference · doi:10.1007/springerreference_39918 · Cited by 1,944
Kingsley, D. M. (1994) · Genes & Development · doi:10.1101/gad.8.2.133 · Cited by 1,933
Dennler, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3091 · Cited by 1,793
Cited by
Complex networks orchestrate epithelial–mesenchymal transitions
Thiery, J. P., & Sleeman, J. P. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1835 · Cited by 3,958
Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness
Zieman, S. J., Melenovsky, V., & Kass, D. A. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000160548.78317.29 · Cited by 1,854
TGF-β and epithelial-to-mesenchymal transitions
Zavadil, J., & Böttinger, E. P. (2005) · Oncogene · doi:10.1038/sj.onc.1208927 · Cited by 1,578
Chronic kidney disease: the global challenge
El Nahas, A. M., & Bello, A. K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17789-7 · Cited by 1,195
Regulation of the Inflammatory Response in Cardiac Repair
Frangogiannis, N. G. (2012) · Circulation Research · doi:10.1161/circresaha.111.243162 · Cited by 1,194
TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease
Willis, B. C., & Borok, Z. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00163.2007 · Cited by 1,042
Moustakas, A., & Heldin, C.-H. (2005) · Journal of Cell Science · doi:10.1242/jcs.02554 · Cited by 958
The role of TGF-β signaling in myocardial infarction and cardiac remodeling
BUJAK, M., & FRANGOGIANNIS, N. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.10.002 · Cited by 927
Pulmonary fibrosis: pathogenesis, etiology and regulation
Wilson, M. S., & Wynn, T. A. (2009) · Mucosal Immunology · doi:10.1038/mi.2008.85 · Cited by 822
Stromal myofibroblasts are drivers of invasive cancer growth
De Wever, O., Demetter, P., Mareel, M., & Bracke, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23925 · Cited by 722
Gressner, A. M., & Weiskirchen, R. (2006) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2006.tb00292.x · Cited by 718
“Hence, given the prominent role of Smad3 in mediating the pathobiology of fibrotic diseases, inhibition of Smad3 signalling could be a prime target for intervention in fibrotic conditions (for review see [57]).”
BackgroundThe immune system and cardiac repair
FRANGOGIANNIS, N. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.06.007 · Cited by 641
Role of transforming growth factor-β superfamily signaling pathways in human disease
Gordon, K. J., & Blobe, G. C. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.01.006 · Cited by 641
Transforming growth factor-β and fibrosis
Verrecchia, F., & Mauviel, A. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i22.3056 · Cited by 510
Regulation of TGF-β signaling by Smad7
Yan, X., Liu, Z., & Chen, Y. (2009) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmp018 · Cited by 436
Dobaczewski, M., Bujak, M., Li, N., Gonzalez-Quesada, C., Mendoza, L. H., Wang, X.-F., & Frangogiannis, N. G. (2010) · Circulation Research · doi:10.1161/circresaha.109.216101 · Cited by 385
Cytokine mediated tissue fibrosis
Borthwick, L. A., Wynn, T. A., & Fisher, A. J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.09.014 · Cited by 375
TGF‐β signaling: A tale of two responses
Rahimi, R. A., & Leof, E. B. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21501 · Cited by 371
Segura, A. M., Frazier, O. H., & Buja, L. M. (2014) · Heart Failure Reviews · doi:10.1007/s10741-012-9365-4 · Cited by 371
Essential Role of Smad3 in Infarct Healing and in the Pathogenesis of Cardiac Remodeling
Bujak, M., Ren, G., Kweon, H. J., Dobaczewski, M., Reddy, A., Taffet, G., Wang, X.-F., & Frangogiannis, N. G. (2007) · Circulation · doi:10.1161/circulationaha.107.704197 · Cited by 356
Kaimori, A., Potter, J., Kaimori, J.-Y., Wang, C., Mezey, E., & Koteish, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700998200 · Cited by 355
Potential cellular and molecular causes of hypertrophic scar formation
van der Veer, W. M., Bloemen, M. C. T., Ulrich, M. M. W., Molema, G., van Zuijlen, P. P., Middelkoop, E., & Niessen, F. B. (2009) · Burns · doi:10.1016/j.burns.2008.06.020 · Cited by 353
Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences
Pastor, J. C., Rojas, J., Pastor-Idoate, S., Di Lauro, S., Gonzalez-Buendia, L., & Delgado-Tirado, S. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.07.005 · Cited by 344
Smad2 Protects against TGF-β/Smad3-Mediated Renal Fibrosis
Meng, X. M., Huang, X. R., Chung, A. C. K., Qin, W., Shao, X., Igarashi, P., Ju, W., Bottinger, E. P., & Lan, H. Y. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121244 · Cited by 338
Ward, W. K. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200504 · Cited by 325
Proliferative Vitreoretinopathy: A Review
Idrees, S., Sridhar, J., & Kuriyan, A. E. (2019) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000258 · Cited by 291
Pathogenesis of Myelofibrosis With Myeloid Metaplasia
Tefferi, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.9316 · Cited by 289
Pathological mechanisms and therapeutic outlooks for arthrofibrosis
Usher, K. M., Zhu, S., Mavropalias, G., Carrino, J. A., Zhao, J., & Xu, J. (2019) · Bone Research · doi:10.1038/s41413-019-0047-x · Cited by 285
Vitamin D in inflammatory diseases
Wöbke, T. K., Sorg, B. L., & Steinhilber, D. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00244 · Cited by 284
Puthawala, K., Hadjiangelis, N., Jacoby, S. C., Bayongan, E., Zhao, Z., Yang, Z., Devitt, M. L., Horan, G. S., Weinreb, P. H., Lukashev, M. E., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-806oc · Cited by 272
Saika, S. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700375 · Cited by 270
Pulmonary hypertension in interstitial lung disease: Fig. 1—
Behr, J., & Ryu, J. H. (2008) · European Respiratory Journal · doi:10.1183/09031936.00171307 · Cited by 263
Zhou, B., Liu, Y., Kahn, M., Ann, D. K., Han, A., Wang, H., Nguyen, C., Flodby, P., Zhong, Q., Krishnaveni, M. S., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276311 · Cited by 261
Therapeutic strategies against TGF‐β signaling pathway in hepatic fibrosis
Liu, X., Hu, H., & Yin, J. Q. (2006) · Liver International · doi:10.1111/j.1478-3231.2005.01192.x · Cited by 261
Turley, E. A., Veiseh, M., Radisky, D. C., & Bissell, M. J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1089 · Cited by 253
Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition
Guarino, M., Tosoni, A., & Nebuloni, M. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.02.020 · Cited by 253
Liu, Y., Liu, H., Meyer, C., Li, J., Nadalin, S., Königsrainer, A., Weng, H., Dooley, S., & ten Dijke, P. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.478685 · Cited by 181
Wang, Y., Moges, H., Bharucha, Y., & Symes, A. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.08.006 · Cited by 84
Propolis compound inhibits profibrotic TGF-β1/SMAD signalling in human fibroblasts
Randall, L. J., Bajan, S., Tran, T. D., Harvey, R. J., & Russell, F. D. (2025) · Scientific Reports · doi:10.1038/s41598-025-07918-2 · Cited by 9
Metadata
- Authors
- Flanders, K. C.
- Venue
- International Journal of Experimental Pathology
- Publisher
- Wiley
- Published
- 2004-04
- Volume
- 85
- Issue
- 2
- Pages
- 47-64
- ISSN
- 0959-9673 (ISSN-L)
- 1365-2613
- OpenAlex
- W2133485412
- Cited by
- 608
- References
- 106
- FWCI
- 11.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.